Abstract Alzheimers disease (AD) is a complex neurodegenerative disorder characterized by -amyloid (A) deposition, hyperphosphorylated tau protein, neuroinflammation, and mitochondrial dysfunction
Clarissa Yang, dermatologist-in-chief at Tufts Medical Center and a professor at Tufts University School of Medicine, previously told TODAY.com
Based on these data, the IGF-1 drug itself does not cause oncology, but only has a contraindication to use if you already have cancer or its predisposition (high cancer markers)
We labeled it as a fat loss peptide, but people would put on lean muscle mass, they'd sleep better
They may recommend dose reduction, slower titration, increased hydration, electrolyte supplementation, or concurrent migraine prophylaxis before considering discontinuation
Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage: 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024) 56% cover for diabetes only (down from 66% in 2024) 20% of diabetes-only plans are considering adding obesity coverage Provincial public drug plans still cover semaglutide only for type 2 diabetes not for weight loss
